Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial.

AIMS: To compare the efficacy and safety of basal-plus (BP) insulin regimen with or without sitagliptin in non-critically ill patients with type 2 diabetes (T2D). METHODS: This open-label, randomized clinical trial included inpatients with a previous diagnosis of T2D and blood glucose (BG) between 180 and 400 mg/dL. Participants received basal and correctional insulin doses (BP regimen) either with or without sitagliptin. The primary outcome was the difference in the mean daily BG among the groups. RESULTS: Seventy-six patients (mean age 60 years, 64 % men) were randomized. Compared with BP insulin therapy alone, the sitagliptin-BP combination led to a lower mean daily BG (158.8 vs 175.0 mg/dL, P = 0.014), a higher percentage of readings within a BG range of 70-180 mg/dL (75.9 % vs 64.7 %, P < 0.001), and a lower number of BG readings >180 mg/dL (P < 0.001). Sitagliptin-BP resulted in fewer basal and supplementary insulin doses (P = 0.024 and P = 0.017, respectively) and lower daily insulin injections (P = 0.023) than those with insulin alone. The proportion of patients with hypoglycemia was similar in the two groups. CONCLUSIONS: For inpatients with T2D and hyperglycemia, the sitagliptin and BP regimen combination is safe and more effective than insulin therapy alone. CLINICALTRIALS: gov identifier: NCT05579119.

[Integrated Care Protocol: Hypertension]. / Protocolo de Atención Integral: hipertensión arterial sistémica.

Background: Hypertension is the most common cardiovascular risk factor that is responsible for complications such as cerebrovascular events, heart failure, acute myocardial infarction, kidney failure, arrhythmias and blindness. About 30% of the adult population older than 20 years is a carrier. 40% of carriers are unaware of suffering from it since its onset is generally asymptomatic. Unfortunately, of those who are already known to be hypertensive, only half take drug treatment and of these, only half achieve control figures (<14/90 mmHg). For several decades it has not been possible to forcefully modify the natural history of this disease despite the advancement of therapeutic drugs. The Mexican Institute of Social Security launches the initiative of the Integrated Care Protocols (PAI) of the main diseases. This protocol shows how the three levels of medical care are concatenated, the role of each of the members of the multidisciplinary team for medical care, including: doctor, nurse, social work, psychologist, nutritionist, among others and, to patient sharing. The main changes in diagnostic criteria, in-office and out-of-office blood pressure measurement, drug therapy (monotherapy, dual therapy and triple therapy) and non-drug therapy, and follow-up are presented. The diagnostic-therapeutic approach using algorithm as well as the diagnostic approach to secondary hypertension and special forms of hypertension such as in pregnancy, hypertensive crisis, hypertension in the elderly, ischemic or nephropathy patients.

Introducción: la hipertensión arterial sistémica (HAS) es el factor de riesgo cardiovascular más común y es responsable de complicaciones como evento cerebrovascular, insuficiencia cardiaca, infarto agudo de miocardio, insuficiencia renal, arritmias y ceguera. Alrededor del 30% de la población adulta mayor de 20 años es portadora. El 40% de los portadores ignoran padecerla ya que su inicio generalmente es asintomático. Desafortunadamente de los que ya se saben hipertensos solo la mitad toma tratamiento farmacológico y de estos, tan solo la mitad logra cifras de control (< 140/90 mmHg). Durante varias décadas no se ha logrado de forma contundente modificar la historia natural de esta enfermedad pese al avance fármaco terapéutico. El Instituto Mexicano del Seguro Social, lanza la iniciativa de los Protocolos de Atención Integral (PAI) de las principales enfermedades. En el presente protocolo se muestra cómo se concatenan los tres niveles de atención médica, el papel de cada uno de los integrantes del equipo multidisciplinario para la atención médica, incluyendo: médico, enfermera, trabajo social, psicólogo, nutricionista, entre otros y, la coparticipación del paciente. Se presentan los principales cambios en criterios diagnósticos, medición de la presión arterial dentro y fuera de consultorio, terapéutica farmacológica (monoterapia, terapia dual y terapia triple), no farmacológica y seguimiento. El Abordaje diagnóstico-terapéutico usando algoritmos, así como también el abordaje diagnóstico de la hipertensión secundaria y formas especiales de hipertensión tales como en el embarazo, crisis hipertensivas, hipertensión en el adulto mayor, pacientes isquémicos o con nefropatía.

Relación de la presión sistólica de la arteria pulmonar medida por ecocardiograma con el tiempo y el tipo de terapia de reemplazo renal / The relationship between systolic pressure of the pulmonary artery measured by echocardiogram and the duration and type of renal replacement therapy

Resumen Introducción: Las alteraciones secundarias a la enfermedad renal crónica (ERC), como inflamación sistémica, anemia y sobrecarga hídrica, son un sustrato importante para el desarrollo de hipertensión arterial pulmonar. Objetivo: Valorar la relación de la presión sistólica de la arteria pulmonar (PSAP) por ecocardiograma con el tiempo y el tipo de terapia de reemplazo renal (TRR) en pacientes con ERC. Método: Estudio observacional, retrospectivo, llevado a cabo en el Hospital de Especialidades del Centro Médico Nacional La Raza, en el que se analizaron medidas de tendencia central y medidas de dispersión. Para comparar porcentajes se utilizó la prueba de χ2 con el programa estadístico SPSS 25. Resultados: Se incluyeron 141 pacientes con ERC en TRR con diálisis peritoneal o hemodiálisis. Se clasificaron de acuerdo con la PSAP en normal (30 pacientes, 21.28%), leve (43 pacientes, 30.5%), moderada (16 pacientes, 12%) y grave (52 pacientes, 36.88%). El tiempo de TRR está relacionado con una PSAP mayor, con 3.53 años en caso de PSAP normal, 5.51 años en caso de PSAP leve, 6.00 años para la PSAP moderada y 6.38 años para la PSAP grave. La PSAP grave se presentó en 13 de 56 pacientes en diálisis peritoneal y en 39 de 85 en hemodiálisis (p = 0.034). Conclusiones: Se encontró que existe relación entre la PSAP con el tiempo y el tipo de sustitución renal en pacientes con ERC.

Abstract Introduction: The disorders secondary to chronic kidney disease (CKD), such as systemic inflammation, anemia, and fluid overload are an important substrate for the development of pulmonary arterial hypertension. Objective: To assess the relationship between pulmonary artery systolic pressure (PASP) on echocardiogram and the duration and type of renal replacement therapy (RRT) in patients with CKD. Method: A retrospective observational study at Hospital de Especialidades del Centro Médico Nacional La Raza. The analysis was performed using measures of central tendency and dispersion. Chi square was used to compare percentages through the SPSS 25 statistical program. Results: A total of 141 patients with CKD on RRT with peritoneal dialysis or hemodialysis were included. They were classified according to PASP as normal (30 patients, 21.28%), mild (43 patients, 30.5%), moderate (16 patients, 12%) and severe (52 patients, 36.88%). The duration of RRT is related to a higher PASP, with 3.53 years for a normal PASP, 5.51 years for mild PASP, 6.00 years for moderate PASP, and 6.38 for those with severe PASP. Severe PASP occurred in 13 of 56 patients on peritoneal dialysis and 39 of 85 patients on hemodialysis (p = 0.034). Conclusions: This study found a relationship between PASP and the duration and type of renal replacement in patients with CKD.

Cardiac and obstetric outcomes in pregnant patients with heart disease: a retrospective cohort study.

BACKGROUND: Cardiac diseases complicate 4% of pregnancies, with a mortality rate between 0 and 15%. Early referral has shown to reduce the risk of maternal major cardiac events (MACEs). METHODS: We retrospectively analyzed a cohort of pregnant women with heart disease from two referral centers in Mexico City. We examined MACEs: maternal death, pulmonary edema, acute heart failure, endocarditis, stroke, myocardial infarction, acute aortic syndromes, arrhythmias requiring urgent treatment, and the need for an urgent intervention; preterm birth and obstetric events such as HELLP syndrome, preeclampsia, eclampsia, placental abruption, obstetric hemorrhage. We analyzed the association between each modified World Health Organization (mWHO) group and MACEs, preterm birth and obstetric outcomes between March 2014 and March 2019. RESULTS: Using the mWHO classification, 399 deliveries were included and stratified as follows: I, 162; II, 133; II-III, 21; III, 18; and IV, 52 patients. MACEs were observed in 12.5% of the cohort and were associated with mWHO II (odds ratio [OR], 3.0; 95% confidence interval [95% CI], 1.1-8.1; p = 0.027), II-III (OR, 3.3; 95% CI, 0.9-1.0; p = 0.116), III (OR, 5.3; 95% CI, 1.2-23; p = 0.026), and IV (OR, 8.2; 95% CI, 2.7-24.5; p < 0.001) after adjusting for age, desaturation, previous functional class, and gestational age at referral. An association between mWHO and frequency of preterm birth was observed. Association between mWHO and obstetric events, even when adjusted, was not observed. CONCLUSIONS: The prevalence of MACEs and preterm birth is similar to that seen worldwide; MACEs and preterm birth are associated with the severity of heart disease stratified by mWHO, but there is no association between the severity of heart disease and obstetric events.